Navigation Links
Amylin Pharmaceuticals Reports 2010 Financial Results
Date:1/26/2011

d-on therapy to basal insulin, with or without metformin and/or a TZD in conjunction with diet and exercise for adults with type 2 diabetes who are not achieving adequate glycemic control.
  • Lilly received approval of BYETTA in Canada for the treatment of adults with type 2 diabetes for use as a combination therapy with metformin and/or a sulfonylurea to improve blood sugar control in adults with type 2 diabetes who have not achieved adequate glycemic control on maximally tolerated doses of these oral therapies, in addition to diet and exercise.

  • Lipodystrophy Program

  • Submitted the initial sections of a rolling submission for a Biologics License Application (BLA) to the FDA for the use of metreleptin to treat diabetes and/or hypertriglyceridemia in patients with rare forms of lipodystrophy. The Company plans to submit the chemistry, manufacturing and controls (CMC) section of the BLA by the end of 2011, which will complete the submission.

  • Corporate

  • Announced research collaboration agreement with the Juvenile Diabetes Research Foundation to provide financial support for a clinical proof-of-concept study to investigate the effects of metreleptin, an analog of the human hormone leptin, in patients with type 1 diabetes.

  • Quarter Ended December 31, 2010Net product sales of $162.3 million for the quarter ended December 31, 2010 include U.S. sales of $136.4 million for BYETTA and $25.9 million for SYMLIN® (pramlintide acetate) injection. This compares to net product sales of $184.3 million, consisting of $163.7 million for BYETTA sales in the U.S. and $20.6 million for SYMLIN for the same period in 2009.

    Revenue under collaborative agreements was $11.9 million for the quarter ended December 31, 2010, compared to $1.3 million for the same period in 2009. In 2010, revenues under collaborative agreements consist of a $10.0 million milestone payment earned upon Lilly's December 2010 launch o
    '/>"/>

    SOURCE Amylin Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Amylin Pharmaceuticals to Webcast Year-End Financial Results
    2. Amylin Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
    3. Amylin Submits Clinical and Nonclinical Sections of Rolling Biologics License Application for Metreleptin to Treat Rare Forms of Lipodystrophy
    4. Amylin Pharmaceuticals Reports Third Quarter Financial Results
    5. Amylin Pharmaceuticals to Present at the 2010 Credit Suisse Healthcare Conference
    6. Amylin, Lilly and Alkermes Announce Receipt of Complete Response Letter from FDA for BYDUREON™
    7. Amylin Pharmaceuticals to Webcast Third Quarter Results
    8. Amylin Pharmaceuticals to Present at the Wedbush Life Sciences Conference 2010
    9. Amylin Pharmaceuticals Appoints Christian Weyer, MD Senior Vice President, Research and Development
    10. Amylin Pharmaceuticals to Present at The Barclays Capital 2010 Global Healthcare Conference
    11. Amylin and Takeda Announce Decision to Advance Development of Pramlintide/Metreleptin Combination Treatment for Obesity
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/24/2014)... , Dec. 23, 2014  Lockton Dunning ... of Lockton Companies, announced the addition of Vice ... will join Lockton Dunning,s Pharmacy Consulting team, Excelsior ... of relevant industry experience to the position.  Most ... Market Sales at Diplomat Specialty Pharmacy, where she ...
    (Date:12/24/2014)... , Dec. 23, 2014 Tianyin ... company that specializes in patented biopharmaceutical, modernized traditional ... ingredients (API) today announced that the Company achieved ... Good Manufacturing Practice (GMP) certificate of TPI,s Qionglai ... Administration,s (CFDA). The public notice period is a ...
    (Date:12/24/2014)... and RALEIGH, N.C. , Dec. ... Endo International plc (NASDAQ: ENDP ) (TSX: ... BDSI ) announced today that they have submitted a ... to the U.S. Food and Drug Administration (FDA).  Buprenorphine ... of pain severe enough to require daily, around-the-clock, long-term ...
    Breaking Medicine Technology:Kim Foerster Joins Lockton Companies 2TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5
    ... Mass., Nov. 1, 2010 Hologic, Inc. (Hologic ... a leading developer, manufacturer and supplier of premium ... dedicated to serving the healthcare needs of women, ... American Society of Breast Surgeons (ASBS) MammoSite® Breast ...
    ... SINGAPORE, Nov. 1, 2010 Flextronics (Nasdaq: ... will open a dedicated, 180,000 square foot facility ... a significant rise in demand from medical OEMs, ... our customers, needs.  Flextronics Medical,s new clean room ...
    Cached Medicine Technology:Hologic Announces Long-term, Five-year Results from MammoSite® ASBS Registry Study 2Hologic Announces Long-term, Five-year Results from MammoSite® ASBS Registry Study 3Flextronics Medical to Open Malaysia Facility to Complement Existing Low-Cost Footprint and Support Growth for Manufacturing Services 2
    (Date:12/24/2014)... TX (PRWEB) December 24, 2014 Connie ... specialist and functional medicine advocate with 30 years of ... trial to evaluate the health benefits of dietary detoxification. ... with new participants following excellent results from test patients ... When asked to explain her interest in conducting the ...
    (Date:12/24/2014)... New York (PRWEB) December 24, 2014 ... mount in a mass tort litigation currently underway in ... reports. As of December 24, 2014, court documents ... proceeding on behalf of individuals who developed gynecomastia (male ... use. Data from the Court indicates that this represents ...
    (Date:12/24/2014)... December 24, 2014 Dr. Vu Ho, ... expansion of his practice and med-spa with the addition ... growing list of cosmetic treatments and services. , “Silk ... the skin,” says Dr. Ho. “As a result it ... as wrinkles, sun spots, discolorations or blemishes.” , Similar ...
    (Date:12/24/2014)... (PRWEB) December 25, 2014 Today, UWDress.com, the ... long sleeve wedding gowns, and launched a site-wide wedding gown ... long sleeve wedding gowns in a more unexpected way, the ... company are popular in the global market, and they are ... at UWDress.com are offered at discounted prices, up to 75% ...
    (Date:12/24/2014)... Dallas, TX (PRWEB) December 25, 2014 ... Analysis to 2023” focuses on the current treatment landscape, ... colorectal cancer market. Stivarga is a drug which is ... This drug is orally administered and is also prescribed ... The drug which is FDA approved is a multi-kinase ...
    Breaking Medicine News(10 mins):Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 4Health News:Dr. Vu Ho Expands Facial Plastic Surgery Practice to Include New Skin Care Treatment 2Health News:Buy Cheap Long Sleeve Wedding Gowns At UWDress.com 2Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3
    ... A team of scientists has found a way to induce nerve ... to protect the cells from the damage // caused by stress ... on a compound found in the body. The findings might give ... as Alzheimer’s. ,This approach works by inducing nerve cells ...
    ... detected in Australia. An elderly woman died on 8th January at ... of cancer // . She was tested positive for Listeria. ... health care officials in Australia. This woman came from interstate and ... the hospital authorities say that the cause of death cannot be ...
    ... is reported to be on the decline. The current winter figures are ... figure // has been on the decline since 2001. The threat from ... to be the immunity that the people in the country have gained ... every year. ,Most of the infected in the current ...
    ... There is a greater chance of people who undergo a ... new research which correlated simultaneous changes // in blood ... of what is known about the brain and its links ... on animals. But the new study on humans used functional ...
    ... the mantra, “Be healthy, be vegetarian!” This is inferred by ... rich in veggies, whole grains and fruits to promote good ... of researchers of London's Imperial College. Their findings were that ... more likely to maintain better cardiovascular health than their carnivorous ...
    ... and insects might have a lot in common while gaining fat. ... when it comes to fat formation in the case of mice ... reveals the effect that genes have on fat storage. The Hh ... are meant for the bone or fat. ,The ...
    Cached Medicine News:Health News:Therapy inducing self-repair of nerves to help Alzheimer’ 2Health News:Several helping of fruits and vegetables help the pressure off the pump- the heart! 2
    10:1 Zoom Ratio - The parallel optical system of the SMZ-1000 has a 10:1 zoom with clickstops at 1X intervals. It features a zoom range of 0.8X to 8.0X and total magnification (depending on eyepieces...
    Fixed Versatility - With a diverse selection of body tubes, stands, lighting techniques and Nikon's world-renowned optics, this modular microscope can be configured to fit nearly any application....
    ... a zoom ratio of 15:1, ... to 11.25X, and the convenience ... from 1X to 11X, observation ... of 3.75X to 540X can ...
    ... 40x/1.2W Corr was designed to have the ... aqueous specimens (vital sections, cell cultures, specimens ... compensating differences in cover glass thickness (0.14...0.18 ... 37C). The correction collar can also ...
    Medicine Products: